Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
3.35(c) 3.35(c) 3.31(c) 3.28(c) 3.29(c) Last
336 901 292 458 245 960 234 809 176 854 Volume
+1.21% 0.00% -1.19% -0.91% +0.30% Change
More quotes
Bioporto A/S is an in-vitro diagnostics company which provides healthcare professionals in clinical and research settings, a range of diagnostic tests and antibodies.It provides antibodies within medical specialties such as obesity, diabetes and primary immune deficiency.The company was founded on... 
11/07Earnings Release
More about the company
Latest news on BIOPORTO A/S
08/10 BIOPORTO A/S : Correction to announcement no 11 - Managers’ transactions
08/10 BIOPORTO A/S : Managers’ transactions
08/02 BIOPORTO A/S : Impact of Near Real-Time NGAL assessment on Clinical Practice
07/14 BIOPORTO A/S : Strong data from previous NGAL study provides the basis for new p..
06/12 BIOPORTO A/S : Diagnostics exhibits at the 35th Vicenza Course on AKI & CRRT fro..
06/07 NGAL DEMONSTRATES POSITIVE ECONOMIC : Greatly Reduces Costs Associated With Dia..
06/07 NGAL DEMONSTRATES POSITIVE ECONOMIC : Greatly Reduces Costs Associated With Dia..
05/04 BIOPORTO A/S : Interim report, first quarter of 2017
05/01 BIOPORTO A/S : Invitation to investor meeting in Århus
04/21 BIOPORTO A/S : Annual General Meeting
More news
Sector news : Diagnostic & Testing Substances Manufacturers
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
04/12BioPorto Release: First Patient Recruited For The NGAL Test Clinical Study In.. 
04/12BioPorto A/S : First patient recruited for The NGAL Test™ clinical .. 
01/30BioPorto A/S: BioPorto completes pre-submission discussions with the FDA #Fin.. 
2016BioPorto A/S: BioPorto expands its NGAL related patent portfolio #Finanzierun.. 
More tweets
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
Peter Mørch Eriksen Chief Executive Officer
Thomas Magnussen Chairman
Jan Kuhlmann Andersen Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.63%352 651
NOVARTIS11.88%224 990
ROCHE HOLDING LTD.6.19%220 358
PFIZER10.81%214 146
MERCK AND COMPANY11.75%177 633